What is Leerink Partnrs' Forecast for CRSP FY2024 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Leerink Partnrs upped their FY2024 EPS estimates for CRISPR Therapeutics in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($5.45) for the year, up from their previous estimate of ($5.88). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.57) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics' Q4 2024 earnings at ($1.52) EPS and FY2025 earnings at ($5.71) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same quarter last year, the company posted ($1.41) EPS.

A number of other equities analysts have also weighed in on the company. Truist Financial lowered their target price on CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating on the stock in a research report on Monday, August 12th. Needham & Company LLC reiterated a "buy" rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday. Royal Bank of Canada reiterated a "sector perform" rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday. Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Finally, Chardan Capital dropped their price target on CRISPR Therapeutics from $112.00 to $94.00 and set a "buy" rating on the stock in a research note on Tuesday, August 6th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $74.94.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded down $0.26 during midday trading on Friday, reaching $51.62. 1,304,947 shares of the company's stock traded hands, compared to its average volume of 1,455,758. The company has a market cap of $4.39 billion, a price-to-earnings ratio of -16.06 and a beta of 1.67. The company's 50 day simple moving average is $47.38 and its 200 day simple moving average is $52.24. CRISPR Therapeutics has a 52 week low of $43.42 and a 52 week high of $91.10.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 4,293 shares of the firm's stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the firm's stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several large investors have recently modified their holdings of the stock. Capital International Investors increased its position in CRISPR Therapeutics by 27.8% during the first quarter. Capital International Investors now owns 7,837,074 shares of the company's stock worth $534,175,000 after buying an additional 1,702,624 shares during the period. Vanguard Group Inc. lifted its holdings in shares of CRISPR Therapeutics by 2.9% during the first quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company's stock valued at $111,564,000 after purchasing an additional 46,148 shares during the last quarter. SR One Capital Management LP bought a new stake in CRISPR Therapeutics during the 1st quarter worth approximately $71,496,000. Dimensional Fund Advisors LP increased its stake in shares of CRISPR Therapeutics by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company's stock valued at $51,326,000 after buying an additional 19,094 shares in the last quarter. Finally, Farallon Capital Management LLC bought a new stake in CRISPR Therapeutics in the 2nd quarter valued at $28,625,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.